Recombinant human FGFR2(IIIc) protein (C-6*HIS)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

C-6*HIS

Activity

EC50: 4-17 ng/mL

Cat no : Eg1265

---

Validation Data Gallery

• 

  Immobilized Human FGFR2 (His tag) at 2 μg/mL (100 μL/well) can bind Human FGF1 (rFc tag) with a linear range of 4-17 ng/mL.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Immobilized Human FGFR2 (His tag) at 2 μg/mL (100 μL/well) can bind Human FGF1 (rFc tag) with a linear range of 4-17 ng/mL.

• Expression: HEK293-derived Human CD28 protein Arg22-Glu377 (Accession# P21802-1) with a human IgG1 Fc tag at the C-terminus.
• GeneID: 2263
• Accession: P21802-1
• PredictedSize: 40.3 kDa
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

FGFR2 (Fibroblast growth factor receptor 2) is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis. Ligand binding leads to the activation of several signaling pathway, such as RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP Kinase signaling pathway, as well as the AKT1 signaling pathway. Mutations in the gene of FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis.

References:

1.Eswarakumar VP, et al. (2005). Cytokine Growth Factor Rev. 16(2):139-149.
2.Pike, KG. (2017). Topics in Medicinal Chemistry. 8.
3.Azoury SC, et al. (2017). Int J Biol Sci. 13(12):1479-1488.